The Latest Breaking News on Pharma

The World Health Organization says that fighters in Sudan have occupied the national public laboratory holding samples of diseases including polio and measles, creating an "extremely, extremely dangerous" situation.

ALLpaQ recognised for outstanding international trade after role in US vaccine roll-out

The healthcare industry should thrive with accelerated breakthrough developments and a growing market for telemedicine and personalized medicines. Moreover, given the lingering macroeconomic headwinds, fundamentally strong healthcare stocks, Amgen (AMGN), and Otsuka Holdings (OTSKY) showing Stability with A and B POWR Ratings could be ideal buys. Read more.

The biopharmaceutical industry has been grappling with various challenges, including inflation, the Fed’s hawkish stance, and new regulatory concerns. Hence, it could be wise to avoid Syndax Pharmaceuticals (SNDX), Senseonics Holdings (SENS), and Sio Gene Therapies (SIOX) due to their bleak fundamentals. Keep reading….

Coupled with fears about an economic downturn, several other headwinds could keep the biotechnology industry under significant pressure. Given this backdrop, fundamentally weak biotech stocks Day One Biopharmaceuticals (DAWN), Northwest Biotherapeutics (NWBO), and Ocugen (OCGN), with bearish momentum, could be avoided in April. Read on….

WASHINGTON — The Supreme Court gave itself more time on a decision expected Wednesday about a commonly used abortion drug, extending until Friday a temporary pause on a lower court ruling that would restrict availability of mifepristone.

A generic-mifepristone maker sued the U.S. Food and Drug Administration to protect access to the medical abortion pill amid a welter of litigation stretching from Texas to Washington.

The court has given itself until Friday to rule on whether to allow restrictions to take effect on mifepristone as legal challenges to its FDA approval continue.

GenBioPro, which makes a generic form of mifepristone, is suing the FDA seeking to preserve access to the drug amidst ongoing federal litigation.